iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It’s FastPharming® and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce biologics.
December 28, 2020
iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer
BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), ...
December 1, 2020
iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins
BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), ...
November 24, 2020
iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis
- Methods for Production in iBio’s FastPharming® System Foundational to Antifibrotic Development ...